Soligenix gets the right to acquire a novel topical formulation of Pentoxifylline (non-biological anti-TNF-alpha inhibitor) for the treatment of mucocutaneous ulcers in patients with Behçet’s Disease (BD)
In the P-II POC study, the results showed an accelerated oral ulcer healing and decreased pain over SoC in patients with BD & was found to be superior to colchicine, patients had index ulcer area shrinkage by Day 2 & undetectable index mouth ulcer by Day 4 (83% & 72% vs 19% vs 29%), pain scores were also found to decrease, no serious AEs were seen & consistent with the systemic use of PTX in the published literature
PTX received ODD & FTD from the US FDA & was being developed under a 505(b)(2) accelerated regulatory pathway in the US
Ref: Soligenix | Image: Soligenix
